Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation 1. While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growin...

詳細記述

書誌詳細

主要な著者:	Céline Eldani, Marie Kostine, Maxime Faure, Estibaliz Lazaro, Claire Rigothier, Jean Baptiste Hiriart, Bérénice Teulières, Florian Poullenot, Magalie Haissaguerre, Maeva Zysman, Rémi Veillon, Charlotte Vergnenegre, Nahema Issa, Charlotte Domblides, Sorilla Mary-Prey, Marie Beylot-Barry, Anne Pham-Ledard, Caroline Dutriaux, Guilhem Sole, Fanny Duval, Emilie Gerard
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2024-07-01
シリーズ:	Frontiers in Oncology
主題:	immune checkpoint inhibitors (ICIs) immune related adverse events (irAEs) rechallenge neurological immune-related adverse events myocarditis
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1403658/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!